Silverarc Capital Management LLC Purchases New Position in uniQure (NASDAQ:QURE)

Silverarc Capital Management LLC purchased a new position in shares of uniQure (NASDAQ:QURE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 100,000 shares of the biotechnology company's stock, valued at approximately $1,766,000. Silverarc Capital Management LLC owned approximately 0.21% of uniQure at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure during the 4th quarter valued at $38,410,000. Franklin Resources Inc. lifted its stake in shares of uniQure by 33.1% in the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock valued at $35,103,000 after purchasing an additional 494,726 shares during the period. Invesco Ltd. boosted its position in shares of uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after purchasing an additional 502,684 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of uniQure by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock valued at $9,198,000 after purchasing an additional 11,951 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in uniQure by 14.7% during the fourth quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock worth $8,014,000 after purchasing an additional 58,246 shares during the period. Institutional investors own 78.83% of the company's stock.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 14,341 shares of the stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the completion of the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock valued at $961,401 in the last quarter. Insiders own 4.74% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on QURE shares. Royal Bank of Canada restated an "outperform" rating and set a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. StockNews.com raised uniQure to a "sell" rating in a research report on Tuesday, March 11th. Chardan Capital initiated coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a "buy" rating and a $38.00 price target for the company. Wells Fargo & Company cut their target price on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $38.80.

uniQure Trading Down 0.6 %

QURE stock traded down $0.08 during midday trading on Friday, hitting $14.18. The company had a trading volume of 646,241 shares, compared to its average volume of 1,777,921. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock's 50 day moving average price is $11.94 and its 200 day moving average price is $11.58. The stock has a market cap of $766.81 million, a price-to-earnings ratio of -2.86 and a beta of 0.42.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.